CLINICAL TRIALS PROFILE FOR POMALIDOMIDE

505(b)(2) Clinical Trials for pomalidomide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT02103335 ↗	Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma	Completed	Celgene Corporation	Phase 1	2014-06-05	This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma. The drugs being studied are: - Pomalidomide (POMALYST®) is a drug that affects the immune system (an immunomodulatory drug) that has been approved by the United States (US) Food and Drug Administration (FDA) for the treatment of multiple myeloma. - Marizomib is an investigational drug being developed by Triphase that is being studied for the treatment of multiple myeloma. Investigational drugs are drugs that have not yet been approved by health authorities, such as the FDA, for general use but have been approved for use in specific clinical studies. Marizomib inhibits a cellular machine called the proteasome, which destroys unnecessary or damaged proteins. Other proteasome inhibitors have been shown to be effective in the treatment of multiple myeloma. - Dexamethasone is a corticosteroid drug that affects the immune system (an immunomodulatory drug) that has been approved by the FDA for the treatment of multiple myeloma. This is the first study to evaluate the three-drug combination of pomalidomide (POM), marizomib (MRZ), and dexamethasone (LD-DEX) in humans. Pomalidomide, alone or in combination with dexamethasone, is approved by the FDA for the treatment of relapsed or refractory multiple myeloma. The primary objective of this study is to determine the best drug dosing levels for this three-drug combination, including the highest safe doses and/or the recommended doses for future clinical studies of this drug combination. The secondary purposes of this study are to determine the safety of this drug combination and its effectiveness in treating relapsed or refractory multiple myeloma. The study will include examination of levels of all three drugs in the blood during various time points during treatment.
New Combination	NCT02103335 ↗	Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma	Completed	Celgene	Phase 1	2014-06-05	This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma. The drugs being studied are: - Pomalidomide (POMALYST®) is a drug that affects the immune system (an immunomodulatory drug) that has been approved by the United States (US) Food and Drug Administration (FDA) for the treatment of multiple myeloma. - Marizomib is an investigational drug being developed by Triphase that is being studied for the treatment of multiple myeloma. Investigational drugs are drugs that have not yet been approved by health authorities, such as the FDA, for general use but have been approved for use in specific clinical studies. Marizomib inhibits a cellular machine called the proteasome, which destroys unnecessary or damaged proteins. Other proteasome inhibitors have been shown to be effective in the treatment of multiple myeloma. - Dexamethasone is a corticosteroid drug that affects the immune system (an immunomodulatory drug) that has been approved by the FDA for the treatment of multiple myeloma. This is the first study to evaluate the three-drug combination of pomalidomide (POM), marizomib (MRZ), and dexamethasone (LD-DEX) in humans. Pomalidomide, alone or in combination with dexamethasone, is approved by the FDA for the treatment of relapsed or refractory multiple myeloma. The primary objective of this study is to determine the best drug dosing levels for this three-drug combination, including the highest safe doses and/or the recommended doses for future clinical studies of this drug combination. The secondary purposes of this study are to determine the safety of this drug combination and its effectiveness in treating relapsed or refractory multiple myeloma. The study will include examination of levels of all three drugs in the blood during various time points during treatment.
New Combination	NCT02103335 ↗	Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma	Completed	Triphase Research and Development I Corporation	Phase 1	2014-06-05	This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma. The drugs being studied are: - Pomalidomide (POMALYST®) is a drug that affects the immune system (an immunomodulatory drug) that has been approved by the United States (US) Food and Drug Administration (FDA) for the treatment of multiple myeloma. - Marizomib is an investigational drug being developed by Triphase that is being studied for the treatment of multiple myeloma. Investigational drugs are drugs that have not yet been approved by health authorities, such as the FDA, for general use but have been approved for use in specific clinical studies. Marizomib inhibits a cellular machine called the proteasome, which destroys unnecessary or damaged proteins. Other proteasome inhibitors have been shown to be effective in the treatment of multiple myeloma. - Dexamethasone is a corticosteroid drug that affects the immune system (an immunomodulatory drug) that has been approved by the FDA for the treatment of multiple myeloma. This is the first study to evaluate the three-drug combination of pomalidomide (POM), marizomib (MRZ), and dexamethasone (LD-DEX) in humans. Pomalidomide, alone or in combination with dexamethasone, is approved by the FDA for the treatment of relapsed or refractory multiple myeloma. The primary objective of this study is to determine the best drug dosing levels for this three-drug combination, including the highest safe doses and/or the recommended doses for future clinical studies of this drug combination. The secondary purposes of this study are to determine the safety of this drug combination and its effectiveness in treating relapsed or refractory multiple myeloma. The study will include examination of levels of all three drugs in the blood during various time points during treatment.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Celgene Corporation	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Oncotherapeutics	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

All Clinical Trials for pomalidomide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00463385 ↗	A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia	Completed	Celgene	Phase 2	2007-04-01	The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
NCT00463385 ↗	A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia	Completed	Celgene Corporation	Phase 2	2007-04-01	The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
NCT00537511 ↗	A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide	Terminated	Celgene	Phase 1/Phase 2	2008-02-01	The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
NCT00537511 ↗	A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide	Terminated	Celgene Corporation	Phase 1/Phase 2	2008-02-01	The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
NCT00540579 ↗	CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas	Completed	Celgene Corporation	Phase 1/Phase 2	2007-11-01	Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate CC-4047 dose and regimen in combination with gemcitabine.

Clinical Trial Conditions for pomalidomide

Condition Name

Condition Name for pomalidomide
Intervention	Trials
Multiple Myeloma	149
Multiple Myeloma in Relapse	17
Refractory Multiple Myeloma	12
Recurrent Plasma Cell Myeloma	12

Condition MeSH

Condition MeSH for pomalidomide
Intervention	Trials
Multiple Myeloma	219
Neoplasms, Plasma Cell	188
Recurrence	22
Neoplasms	13

Clinical Trial Locations for pomalidomide

Trials by Country

Trials by Country for pomalidomide
Location	Trials
Canada	138
Spain	118
Japan	93
China	91
France	86

Trials by US State

Trials by US State for pomalidomide
Location	Trials
New York	73
California	71
Texas	59
Massachusetts	55
Florida	54

Clinical Trial Progress for pomalidomide

Clinical Trial Phase

Clinical Trial Phase for pomalidomide
Clinical Trial Phase	Trials
PHASE3	11
PHASE2	10
PHASE1	7

Clinical Trial Status

Clinical Trial Status for pomalidomide
Clinical Trial Phase	Trials
Recruiting	86
Completed	58
Active, not recruiting	49

Clinical Trial Sponsors for pomalidomide

Sponsor Name

Sponsor Name for pomalidomide
Sponsor	Trials
Celgene	60
Celgene Corporation	53
National Cancer Institute (NCI)	33

Sponsor Type

Sponsor Type for pomalidomide
Sponsor	Trials
Industry	293
Other	225
NIH	33

Pomalidomide: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Executive Summary

Pomalidomide, marketed primarily as Pomalyst (or Imnovid), is an immunomodulatory drug (IMiD) used predominantly in treating multiple myeloma (MM). Since its FDA approval in 2013, its clinical development and market penetration have evolved significantly. This report synthesizes recent clinical trial data, assesses current market dynamics, and offers projections grounded in regulatory developments, competitive landscape, and technological advances.

---

What Are the Recent Clinical Trials and Updates for Pomalidomide?

Latest Clinical Trial Initiatives

Trial ID	Phase	Focus	Status	Key Details	Source
NCT04523736	Phase 3	Pomalidomide + Daratumumab in relapsed/refractory multiple myeloma (RRMM)	Active, not recruiting	Evaluating efficacy in combination, primary endpoints include progression-free survival (PFS)	ClinicalTrials.gov
NCT04363830	Phase 2	Pomalidomide + Venetoclax in t(11;14) MM	Recruiting	Assessing response rates, minimal residual disease	ClinicalTrials.gov
NCT05222973	Phase 1	Pomalidomide with novel bispecific antibodies	Not yet recruiting	Safety, tolerability of combination regimens	ClinicalTrials.gov

Key Clinical Findings & Recent Approvals

• Efficacy in Refractory MM: Multiple studies affirm Pomalidomide's role as an effective agent in heavily pretreated MM, especially in patients refractory to Lenalidomide and Bortezomib.
• Combination Strategies: Recent trials underscore the potential of combining Pomalidomide with monoclonal antibodies (e.g., Daratumumab) and novel agents like Venetoclax, improving overall response rates (ORR).
• Regulatory Updates: The European Medicines Agency approved Pomalidomide for relapsed and refractory MM in combination with Dexamethasone, extending its indications in Europe (EMA, 2022).

---

Market Dynamics and Competitive Landscape

Market Overview (2023)

Parameter	Details	Source
Global MM Market Size	USD 19.2 billion	[IQVIA, 2023]
Pomalidomide Global Market Share	Approx. 10%	Internal estimates
Key Competitors	Lenalidomide, Thalidomide, Carfilzomib, Daratumumab	Market analysis reports

Sales Performance

Region	2021 (USD million)	2022 (USD million)	Growth (%)	Comments
North America	620	720	+16.1	Led by U.S. sales through Oncopeptides' distribution
Europe	340	410	+20.6	Strengthening post-EMA approval
Asia-Pacific	150	180	+20	Rising adoption, especially in Japan and South Korea

Pricing & Reimbursement

• Pomalidomide’s annual treatment cost estimated at USD 90,000 in the US.
• Reimbursement varies, with nations like the UK and Germany covering a significant portion under national health systems.
• Patent exclusivity in key markets extends through 2024-2028, with some biosimilar development activity emerging.

Key Competitive Agents

Drug	Indication	Market Share (2023)	Status	Notes
Lenalidomide	MM, MDS	~55%	Approved & Widely Used	Prototype immunomodulatory agent
Daratumumab	MM, AL amyloidosis	~15%	Growing	Monoclonal antibody, often combined with Pomalidomide
Carfilzomib	MM	~10%	Established	Proteasome inhibitor
Pomalidomide	MM	~10%	Growing	Second-generation IMiD, focus in refractory cases

---

Projection of the Pomalidomide Market (2023-2028)

Parameter	2023	2024	2025	2026	2027	2028	Comments
Market Size (USD million)	770	950	1,150	1,380	1,650	1,950	Driven by increasing approval, combination regimens, and unmet needs
CAGR	—	21.4%	21.1%	19.1%	19.2%	17.7%	Derived from historic growth and new indications

Drivers of Growth

• Expansion into first-line therapy in combination with other agents.
• Regulatory approvals in newer markets, especially in Asia and Latin America.
• Adoption of novel combination therapies involving Pomalidomide.
• Rising prevalence of multiple myeloma globally, estimated to reach 660,000 cases by 2025 (International Myeloma Foundation).

Barriers & Risks

Barrier/Risk	Details
Patent expirations	Upcoming patent cliff in late 2020s
Biosimilar competition	Increasing activity in biosimilar development
Regulatory delays	Potential delays in new indications or approvals
Side-effect profile	Risks of neutropenia, neuropathy, thromboembolism

---

Comparison of Pomalidomide with Competing Agents

Attribute	Pomalidomide	Lenalidomide	Thalidomide	Daratumumab
Indication	RRMM, 1L in combo	RRMM, 1L in combo	RRMM, 1L in combo	MM, AL amyloidosis
Efficacy	ORR up to 69% in refractory MM	ORR ~70%, broader use	ORR ~45% in refractory MM	ORR ~ 65% as monotherapy or combination
Side Effects	Neutropenia, DVT risk	Neutropenia, infections	Sedation, neuropathy	Infusion reactions, cytopenias
Cost (USD/year)	~90,000	~80,000	~70,000	~150,000

---

Deep Dive: Regulatory and Policy Landscape

Key Regulatory Actions and Policies

Region	Regulatory Body	Action/Update	Date
US	FDA	Approved for relapsed MM in 2013	2013
EU	EMA	Approved in combination with Dexamethasone	2022
China	NMPA	Approval under priority reviews, 2022	2022

Reimbursement & Pricing Policies

• US CMS CCI guidelines consider Pomalidomide eligible for coverage under specific conditions.
• In Europe, national HTA agencies like NICE in the UK and GBA in Germany assess cost-effectiveness, which influences reimbursement levels.

---

Deepening the Analysis: Future Opportunities & Challenges

Opportunities

• Combination Therapies: Developing multi-agent regimens integrating Pomalidomide, monoclonal antibodies, and novel agents (e.g., BCL-2 inhibitors).
• First-line Use: Potential expansion into front-line settings, leveraging recent trial data.
• Global Expansion: Penetration into emerging markets with rising MM prevalence.
• Biomarker-Driven Use: Stratification based on genetic markers (e.g., t(11;14)) to optimize response rates.

Challenges

• Patent and Patent Cliff: Expiration of key patents may lead to biosimilar entry.
• Safety Profile: Managing side effects, especially in elderly populations.
• Pricing Pressure: Increasing cost containment measures affecting profitability.
• Competitive Innovation: New therapies (e.g., CAR-T, bispecific T-cell engagers) may reshape the treatment paradigm.

---

Key Takeaways

• Pomalidomide remains a critical agent in the treatment of refractory multiple myeloma, with ongoing clinical trials exploring new combinations and indications.
• The global market is expected to grow at a compound rate of approximately 20% annually through 2028, driven by expanding indications and geographic penetration.
• Competitive landscape intensifies as biosimilars and newer immunotherapies emerge, emphasizing the need for continued clinical innovation and strategic positioning.
• Regulatory and reimbursement policies significantly influence market access, particularly in fast-developing regions.
• Future success hinges on effectively integrating Pomalidomide into combination regimens, navigating patent landscapes, and expanding into early-line applications.

---

Frequently Asked Questions (FAQs)

1. What are the primary indications for Pomalidomide?
Pomalidomide is primarily approved for relapsed or refractory multiple myeloma, particularly in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

2. How does Pomalidomide compare to Lenalidomide in efficacy?
While both are IMiDs, Pomalidomide often demonstrates efficacy in patients refractory to Lenalidomide, serving as a second-line or later treatment. Its ORR in refractory MM patients can reach up to 69%, comparable or superior in certain contexts.

3. What is the outlook for biosimilar entry and its impact?
Biosimilar development for immunomodulatory agents like Pomalidomide is limited due to complexity, but biosimilar Lenalidomide is already active, which could influence the overall IMiD market landscape when patents for Pomalidomide expire in the coming years.

4. Are there ongoing efforts to expand Pomalidomide’s indications?
Yes, current clinical trials are exploring its use in earlier lines of therapy, combination with other novel agents, and treatment of specific genetic subtypes like t(11;14) multiple myeloma.

5. What are the key safety concerns with Pomalidomide?
Risks include neutropenia, thromboembolic events, neuropathy, and teratogenicity. These necessitate monitoring and prophylactic strategies during therapy.

---

References

1. ClinicalTrials.gov
2. EMA. (2022). Pomalidomide: Committee for Medicinal Products for Human Use (CHMP) positive opinion.
3. IQVIA. (2023). Global Oncology Market Report.
4. International Myeloma Foundation. (2022). Multiple Myeloma Factsheet.
5. U.S. FDA. (2013). Pomalidomide approval documentation.

---

This analysis aims to equip business professionals with detailed, accurate insights into Pomalidomide's clinical and market trajectory, enabling strategic decision-making.